© 2005 European Society for Medical Oncology
Special article |
Workgroup II: the screening process. UICC International Workshop on Facilitating Screening for Colorectal Cancer, Oslo, Norway (29 and 30 June 2002)
1 Memorial Sloan-Kettering Cancer Center, New York, NY, USA; 2 Faculté de Médecine, Dijon, France; 3 Kaiser Permanente, Northern California, Oakland, CA, USA; 4 National Cancer Institution, Milan, Italy; 5 National Taiwan University, Taipei, Taiwan; 6 Odense University Hospital, Odense, Denmark; 7 UT MD Anderson Cancer Center, Houston, TX, USA; 8 Rollins School of Public Health, Emory University, Atlanta, GA, USA; 9 Adelaide Meath Hospital, Dublin, Ireland; 10 St. Thomas' Hospital, London, UK; 11 Carmel Medical Center, Haifa, Israel; 12 Local Health Authority of Milan, Milan, Italy; 13 Hirosaki University School of Medicine, Aomori, Japan; 14 Central Military Hospital Prague, Prague, Czech Republic; 15 University of Hong Kong, Hong Kong; 16 American Cancer Society, Atlanta, GA, USA
* Correspondence to: Dr R. Smith, American Cancer Society, 1599 Clifton Road NE, Atlanta, GA 30329, USA. Tel: +1-404-329-7610; Email: Robert.Smith@cancer.org
| The first 10% of the full text of this article appears below. |
 |
Introduction |
|---|
The charge to our workgroup was to address the screening process: specifically, for different methods of screening or with multiple options for screening, how should a colorectal cancer screening service be organized, and what national factors might lead to different strategies for screening delivery?
For many years it has been believed that the early detection of colorectal cancer through screening could reduce the burden of this disease in the many countries worldwide in which the risk is high. During the past 30 years this belief has been transformed into a strategic reality. This transformation has resulted from a clearer understanding of the natural history of colorectal cancer as it evolves through the precancerous adenoma stage, and technological advances that permit earlier detection of cancer, detection and removal of adenomas, accurate diagnostic work-up of people with positive screening tests and
|
Current status of screening worldwide |
|---|
|
Key issues in screening |
|---|
|
Barriers and challenges to screening |
|---|
|
Recommendations for action |
|---|
A. Planning the screening program
B. Implementing the screening program
C. Monitoring the screening program
|
Summary |
|---|
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  F. Diehl, M. Li, D. Dressman, Y. He, D. Shen, S. Szabo, L. A. Diaz Jr, S. N. Goodman, K. A. David, H. Juhl, et al. Detection and quantification of mutations in the plasma of patients with colorectal tumors PNAS, November 8, 2005; 102(45): 16368 - 16373. [Abstract] [Full Text] [PDF]
|
|